Healthcare Services

Radiotheranostics Market Outlook 2026–2030 with Major Growth Drivers and Emerging Industry Trends

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Radiotheranostics Market At The End Of The 2026–2030 Forecast Period?

The radiotheranostics market size has experienced rapid growth in recent years. It is projected to expand from $10.05 billion in 2025 to $11.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.7%. The market’s historic period growth can be attributed to the increasing use of nuclear medicine diagnostics, the expansion of oncology-focused clinical research, the availability of therapeutic radioisotopes, the rising adoption of PET and SPECT imaging, and growing collaboration between pharma and imaging providers.

The radiotheranostics market is set to experience significant expansion over the next few years, with its size anticipated to reach $19.24 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.9%. This forecasted growth is driven by several factors, including an increase in approvals for radiotheranostic drugs, escalating investments in precision oncology, the broadening of isotope production infrastructure, a growing demand for personalized cancer care, and the increasing integration of AI in treatment selection. Key trends expected during this period include the rising adoption of targeted radioligand therapies, an increased use of paired diagnostic and therapeutic isotopes, the growing integration of precision imaging and therapy, the expansion of personalized oncology applications, and an enhanced focus on molecular-level cancer targeting.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12270&type=smp

What Drivers Are Shaping The Future Growth Of The Radiotheranostics Market?

A rise in cancer cases is anticipated to drive the expansion of the radiotheranostics market in the future. Cancer refers to a disease where certain body cells multiply without control and extend to different parts of the body. Radiotheranostics medications are frequently utilized in cancer treatment to provide the ultimate concept of personalized medicine, through the application of paired diagnostic and therapeutic radionuclide probes, enabling the precise and targeted identification and therapy of particular (usually cancerous) cells, with each probe tailored to the patient’s specific underlying condition, aiming to improve treatment effectiveness and achieve superior clinical outcomes. For example, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported an increase in cancer cases to 2,001,140 from 1,958,310 in 2023, marking a 2.19% growth. Consequently, the growing incidence of cancer is a key driver for the radiotheranostics market.

What Segment Types Make Up The Radiotheranostics Market?

The radiotheranostics market covered in this report is segmented –

1) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fludeoxyglucose-18F, Yttrium-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioisotopes

2) By Approach: Targeted Therapeutic, Targeted Diagnostic

3) By Application: Oncology, Non-Oncology

4) By End-Users: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Technetium-99: Technetium-99m, Technetium-99 Pertechnetate

2) By Gallium-68: Gallium-68 DOTATATE, Gallium-68 PSMA

3) By Iodine-131: Iodine-131 For Thyroid Cancer Treatment, Iodine-131 For Hyperthyroidism Treatment

4) By Iodine-123: Iodine-123 For Thyroid Scans, Iodine-123 For Cardiac Imaging

5) By Fludeoxyglucose-18F (FDG): FDG For Oncology Imaging, FDG For Brain Imaging

6) By Yttrium-90: Yttrium-90 Microspheres For Liver Cancer, Yttrium-90 For Radioimmunotherapy

7) By Lutetium (Lu) 177: Lutetium-177 PSMA For Prostate Cancer, Lutetium-177 DOTATATE For Neuroendocrine Tumors

8) By Copper (Cu) 67: Copper-67 For Targeted Radiotherapy, Copper-67 In Clinical Trials

9) By Copper (Cu) 64: Copper-64 For PET Imaging, Copper-64 For Radiotherapy

10) By Other Radioisotopes: Radium-223, Samarium-153, Other Emerging Radioisotopes In Theranostics

What Major Market Trends Are Driving Changes In The Radiotheranostics Market?

Leading companies in the radiotheranostics market are prioritizing the development of innovative products to boost the creation and accessibility of therapeutic radioisotopes, refine treatment accuracy, and address the increasing demand for targeted cancer therapies. For example, in May 2023, Advanced Cyclotron Systems Inc., a Canada-based firm specializing in cyclotrons for medical isotope production, unveiled TR-ALPHA. This dedicated cyclotron is designed for manufacturing alpha-emitting radioisotopes used in cancer treatment. Developed to meet the market’s need for an economical cyclotron capable of producing significant quantities of Astatine-211, a highly promising alpha-emitting radioisotope, TR-ALPHA is more compact, affordable, and user-friendly than its predecessors, making it an optimal choice for hospitals, research institutions, and organizations aiming to efficiently produce therapeutic alpha-emitting radioisotopes.

Who Are The Key Players Driving Competition In The Radiotheranostics Market?

Major companies operating in the radiotheranostics market are Lantheus Holdings Inc., Cardinal Health Inc., GE Healthcare Inc., Bayer AG, Novartis AG, Siemens Healthineers, Orano Med, Curium SAS, IBA Molecular, The Eckert & Ziegler Group, Advanced Accelerator Applications (AAA), Telix Pharmaceuticals Limited., Abdera Therapeutics, Blue Earth Diagnostics, Sirtex Medical Limited, Y-mAbs Therapeutics Inc., ITM Radiopharma, NorthStar Medical Radioisotopes LLC, Trasis S.A., Molecular Targeting Technologies Inc., RadioMedix Inc, Clarity Pharmaceuticals, Actinium Pharmaceuticals Inc., Navidea Biopharmaceuticals Inc.

Read the full radiotheranostics market report here:

https://www.thebusinessresearchcompany.com/report/radiotheranostics-global-market-report

Which Geographic Regions Are Influencing Demand In The Radiotheranostics Market?

North America was the largest region in the radiotheranostics market in 2025. The regions covered in the radiotheranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Radiotheranostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12270&type=smp

Browse Through More Reports Similar to the Global Radiotheranostics Market 2026, By The Business Research Company

Radiotherapy Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/radiotherapy-devices-global-market-report

Veterinary Stereotactic Radiosurgery System Global Market Report

https://www.thebusinessresearchcompany.com/report/veterinary-stereotactic-radiosurgery-system-global-market-report

Image Guided Radiation Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/image-guided-radiation-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795